TY  - JOUR
T1  - Generic competition in a flawed system: Pill them, bill them
AU  - Braillon A
Y1  - 2012/10/22
N1  - 10.1001/archinternmed.2012.4389
JO  - Archives of Internal Medicine
SP  - 1522
EP  - 1523
VL  - 172
IS  - 19
N2  - 
The license of some corporations to manipulate the system to suit their interests requires an enduring complacency of the system. Recently, the US Food and Drug Administration, despite the lack of evidence for benefit, granted a new marketing authorization for the 23-mg dose of donepezil hydrochloride in the treatment of Alzheimer disease.2 This allows Pfizer to avoid generic competitors, since the patent for donepezil, first approved in 1996, expired in November 2010. Lastly, could this be a reason why so many physicians prescribe their patients with costly medicines when less expensive ones are available?

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2012.4389
UR  - http://dx.doi.org/10.1001/archinternmed.2012.4389
ER  -